Cyclin–Cyclin-dependent kinase 3 complex (Cyclin–CDK3)

The Cyclin–Cyclin-dependent kinase 3 (Cyclin–CDK3) complex is a heterodimeric enzyme that plays a pivotal role in the mammalian cell cycle, particularly in the transition from the quiescent G0 phase to the G1 phase (UniProt: P33981). It primarily functions by associating with Cyclin C to phosphorylate the retinoblastoma protein (Rb), which facilitates the activation of E2F-mediated transcription and subsequent cell cycle entry (PubMed: 15175241). Although CDK3 is not essential for the survival of all cell types, its dysregulation is strongly linked to the pathogenesis of various cancers, including glioblastoma, breast cancer, and colorectal carcinoma, where it promotes rapid proliferation and transformation (PubMed: 25670303). In the context of drug development, the Cyclin–CDK3 complex is targeted by several small-molecule inhibitors, most of which are pan-CDK inhibitors like Flavopiridol and Dinaciclib that compete for the ATP-binding site (PubMed: 21810924). While these inhibitors show efficacy in arresting the cell cycle, the high degree of structural similarity between CDK family members often leads to off-target effects and dose-limiting toxicities. Current research focuses on identifying more selective CDK3 inhibitors to improve therapeutic indices and better understand the specific contributions of this kinase to oncogenesis (PubMed: 28651084). The complex is also known to interact with Cyclin E during the G1-S transition, suggesting a broader role in cell cycle control than previously understood (PubMed: 10400605). Targeting this complex remains a promising strategy for precision oncology, provided that isoform-specific inhibition can be achieved to minimize systemic adverse events.

Other names

CDK3 complexCyclin C-CDK3 complexCyclin E-CDK3 complexCell division protein kinase 3 complex

Inhibition of the kinase activity by competing with ATP for the binding site, thereby preventing the phosphorylation of downstream substrates like Rb and inhibiting cell cycle progression.